Table 1.

Inhibitory concentrations for STF-118804 and idarubicin on cell lines, patient samples and normal progenitors

Cell Type	STF-118804 IC50 (nM) (± 95% confidence interval)	Idarubicin IC50 (nM) (± 95% confidence interval)
SEM	2.7 (2.3–3.2)	1.0 (0.4–2.4)
KP-Y-RL	2.6 (1.9–3.4)	11.4 (6.8–19.2)
MV411	6.0 (5.2–7.0)	7.6 (3.9–14.9)
Nalm6	8.8 (8.0–9.8)	4.6 (2.8–7.5)
697	8.6 (7.5–9.8)	7.6 (4.3–13.4)
Hal01	9.2 (8.1–10.5)	3.2 (1.9–5.4)
REH	> 10,000	1.5 (0.7–5.4)
SUP-B15	> 10,000	2.8 (1.0–7.5)
MLL-AF4 Patient 1	13.9 (6.3–31.1)	ND
MLL-AF4 Patient 2	32.3 (13.3–78.3)	ND
MLL-AF4 Patient 3	3.1 (1.1–29)	ND
MLL-AF4 Patient 4	5.1 (1.3–20.1)	ND
TEL-AML Patient 5	4.2 (3.1–5.6)	ND
Lin− Cord Blood Cells	40.2 (19.6–82.5)	11.1 (7.5–16.7)
c-kit+ murine BM	62.3 (52.1–74.5)	11.5 (9.0–14.6)

ND, not determined.

Cells were incubated with increasing concentrations of STF-118804 or idarubicin, and viability was assessed using CellTiter-Blue or WST-1 reagent. Assays were performed in triplicate and inhibitory concentrations were calculated using Prism or CalcuSyn software.